In recent years, it has been reported that epidermal growth factor receptor (EGFR) mutations and the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene are involved in the diagnosis of lung cancer, and it is known that the presence or absence of these also affect treatment [1, 2]. This evidence concerns the gene ALK and lung cancer.